SCHEMBL3566434

SCHEMBL3566434

N#Cc1cnc2oc(-c3ccccc3)c(-c3ccccc3)c2c1NCCn1ccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
AURKA O14965 5/20 0.58
KDM4E B2RXH2 4/20 0.58
HPGD P15428 4/20 0.58
HSD17B10 Q99714 4/20 0.58
NPSR1 Q6W5P4 3/20 0.58
USP2 O75604 3/20 0.58
TSHR P16473 3/20 0.58
MAPK1 P28482 3/20 0.58
MAPT P10636 3/20 0.58
LMNA P02545 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
TP53 P04637 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TNK2 Q07912 6/20 0.48
LCK P06239 5/20 0.48
KDR P35968 5/20 0.48
JAK3 P52333 4/20 0.48
GAA P10253 2/20 0.44
HTT P42858 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566479 0.82 KDM4E (0.53) ALDH1A1AURKAKDM4EHPGDHSD17B10
SCHEMBL3572103 0.81 KDM4E (0.52) ALDH1A1AURKAKDM4EHPGDHSD17B10
SCHEMBL3564842 0.81 AURKA (0.48) AURKATNK2LCKKDRJAK3
SCHEMBL3568195 0.80 KDM4E (0.51) ALDH1A1AURKAKDM4EHPGDHSD17B10
SCHEMBL3572129 0.80 LCK (0.65) ALDH1A1AURKAKDM4EHPGDHSD17B10
SCHEMBL3563328 0.79 AURKA (0.51) ALDH1A1AURKAKDM4EHPGDHSD17B10
SCHEMBL3568846 0.79 TNK2 (0.50) AURKATNK2LCKKDRJAK3
SCHEMBL3562107 0.79 AURKA (0.62) ALDH1A1AURKAKDM4EHPGDHSD17B10
SCHEMBL3570864 0.79 ALDH1A1 (0.48) ALDH1A1AURKAKDM4EHPGDHSD17B10
SCHEMBL3579856 0.77 CHEK1 (0.47) ALDH1A1AURKAKDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US claimed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 ALDH1A1 869/4885AURKA 130/4885KDM4E 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.